Association leverages Clarifide® and Clarifide® Ultra to improve breed performance, production
Zoetis and the American Guernsey Association (AGA) today announced a genomic testing agreement to help improve Guernsey breed performance and production objectives. With this agreement, AGA elected to partner exclusively with Zoetis for its leading genomic testing solutions. Association members can make confident genetic selection decisions to advance progress toward a dairy’s goals using Clarifide® and Clarifide® Ultra, two powerful genomic selection tools from Zoetis. Additionally, producers will have access to the new online genomic data management tool, SearchPoint™. With SearchPoint, users can quickly access their genetic test results and easily view them in custom reports, tables and graphs that are shareable with partners and herd advisers.
- Make better-informed decisions on young animals when it comes to selection and breeding.
- Recognize higher-genetic females earlier in life to prioritize and apply advanced reproductive technologies such as sexed semen, embryo transfer and in vitro fertilization to drive faster genetic improvement progress.
- Identify which heifer groups may be of lower economic value, thus better used as recipients for high-quality embryos, bred with conventional semen (taking the normal 50% odds of a heifer) or sold as young calves before an economic investment is made in them.
- Validate and discover parentage to more correctly manage risks of inbreeding with the use of mating programs.
Garnering improved reliability at a very young age is the cornerstone of why producers leverage genomic testing. They can have more confidence in decisions with more than a lifetime of information provided in one test.
AGA members may leverage Clarifide and Clarifide Ultra by submitting samples through the association or directly to Zoetis. To learn more about genomic testing to reach your Guernsey herd’s potential, please visit Clarifide.com or contact AGA or your Zoetis representative.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.